A transplant center designated as a Comprehensive Report Form center will submit data on the Pre-TED and Pre-TED Disease Classification Forms, followed by either the Post-TED Form or the Comprehensive Report Forms. The type of follow-up forms required for a specific recipient is determined by the CIBMTR’s form selection algorithm (see Section 1 in the Center Reference Guide).

The Post-Infusion Form (2100) must be completed at the following time points: 100 days, 6 months, annually for 6 years post-HCT, and biennially thereafter. This form should be completed as closely to these time points as possible. The following recipient data should be collected from an actual examination (or other recipient contact) by the transplant center physician or the local physician who is following the recipient post-HCT: vital status, hematopoietic reconstitution post-HCT, neutrophil recovery, platelet recovery, current hematologic findings, immune reconstitution, chimerism studies, engraftment syndrome, acute Graft-versus-Host Disease (GVHD), chronic GVHD, infections, organ function, new malignancy, functional status, and subsequent HCT.

Subsequent HCT:
If a recipient receives a subsequent HCT between time points (100 day, 6 months, annually), the CRF form sequence will start over again with another Pre-TED.

However, if the recipient receives an autologous HCT as a result of a poor graft or graft failure, the CRF form sequence will not start over again. Generally, this type of infusion (autologous rescue) is used to treat the recipient’s poor graft response, rather than to treat the recipient’s disease, and is, therefore, not considered a subsequent HCT for reporting purposes.

Contact CIBMTR Center Support if the subsequent Pre-TED does not come due automatically.

Lost to Follow Up:
Occasionally, centers may lose contact with recipients for a variety of reasons, including the recipient moving, changing physicians, or death. If contact with a recipient appears lost, please consider calling the recipient at home or work, sending a letter, communicating with the treating or referring physician, or contacting the hospital billing department. If no documentation exists and several unsuccessful attempts have been made to contact the recipient, they are considered lost to follow-up and the form may be marked as such using the Lost to Follow-Up Tool in FormsNet3 for each reporting period in which no contact exists.

Links to Sections of Form:

Q1 – 8: Vital Status
Q9 – 15: Granulopoiesis / Neutrophil Recovery
Q16 – 19: Megakaryopoiesis / Platelet Recovery
Q20 – 28: Growth Factor and Cytokine Therapy
Q29 – 38: Current Hematologic Findings
Q39 – 54: Immune Reconstitution
Q55 – 72: Chimerism Studies
Q73 – 83: Engraftment Syndrome
Q84 – 133: Acute Graft vs. Host Disease
Q134 – 203: Chronic Graft vs. Host Disease
Q204 – 210: Current GVHD Status
Q211 – 226: Infection Prophylaxis
Q227 – 248: Infection
Q249 – 310: Organ Function
Q311: New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder
Q312 – 335: Functional Status
Q336 – 339: Subsequent HCT

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please review the table below or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
9/23/2022 2100:Post-Infusion Follow-Up Form Modify Version 8 of the 2100: Post-Infusion Follow-Up section of the Forms Instructions Manual released. Version 8 corresponds to revision 8 of the Form 2100
Last modified: Sep 23, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.